Still, raloxifene might be considered in post-menopausal women with contraindications to all other drugs, but no contraindication to a selective estrogen receptor modulator (such as increased risk of cardiovascular disease or venous thromboembolism) (91). This evidence concerns the gene ESR1 and cardiovascular disorder.